New Chief Medical Officer (CMO) started at Axinesis from the 1st of September !

Since the 1st of September, a new member has joined Axinesis. Maxime Gilliaux, physiotherapist, doctor in motor sciences and Executive MBA in health, is now our Chief Medical Officer. He becomes our clinical and research referent for all of our collaborators.

Can you introduce yourself in a few words?

My name is Maxime Gilliaux, the new Chief Medical Officer (CMO) at Axinesis. As far as my background is concerned, I am a physiotherapist, a doctor in motor sciences and also hold an Executive MBA in health.

I have had different experiences in clinical, research and management fields.

More specifically, I had the chance to work with a team of researchers, clinicians and engineers linked to UCL, including Julien Sapin, CTO and founder of Axinesis. Together, we produced the first scientific evidences on the interest of the REAplan in the evaluation and rehabilitation of cerebral palsy patients, both adults and children. In terms of management, I created and directed a research department in a rehabilitation hospital while at the same time being part of its management committee as clinical project manager.

I think that the synergy of these skills will be a real asset in my responsibilities as CMO at Axinesis.

What are your responsibilities at Axinesis?

Within Axinesis, I will be the clinical and research referent for patients, health professionals, scientists, authorities, and other collaborators.

My responsibilities will be to bring a clinical and research vision to the company. At the clinical level, we will develop with the team innovative solutions that meet the needs of the patient and the therapist. In addition, we will train them to use our devices in an optimal way. On the research side, we will work with a number of researchers to validate the clinical protocols through scientific publications. 

What is your favorite game on the REAtouch?

I like the REAcooking game because of its graphic and functional aspects for the patient. Moreover, I like cooking a lot and I am very greedy!

Blogpost – Proven effectiveness of early Robotic Assisted Therapy for upper limb rehabilitation after stroke

Workspace of REAplan

Study provides further evidence for the effectiveness of robot-assisted therapy in stroke upper limb rehabilitation

Robot-assisted therapy (RAT) is of significant interest in early rehabilitation, when neuroplasticity is high but motor control is frequently insufficient for patients to independently practice functional movements. Many patients with stroke experience persistent upper limb (UL) impairments. This single-blind, randomized, controlled trial[i] explored the impact of partially substituting conventional therapy (CT) with RAT on the three International Classification of Functioning, Disability and Health (ICF) domains.

MethodsWorkspace of REAplan

Forty-five patients with acute stroke were randomized to receive dose-matched interventions over nine weeks. The first received conventional therapy (CT). In the second group, four CT sessions per week (25%) were substituted by RAT using our REAplan® end-effector robot to perform a game moving the paretic hand along a trajectory, with the robot assisting as needed.

Assessments were performed by the same blinded evaluator at inclusion (T0), after the intervention (TI), and at six months after stroke (T2). They were:

  • Upper limb motor impairments – FMA-UE (motor control) and box and block test (BBT –gross manual dexterity)
  • Activity limitations – Wolf Motor Function Test (S-WMFT), and Abilhand and Activlim questionnaires
  • Social participation – subscore of the Stroke Impact Scale (SISsb).

Results

Main findings were:

  • The RAT group performed a mean (SD) of 520 (437) movements per session.
  • The RAT group showed significantly greater improvement in gross manual dexterity than CT group (P = 0.02). Between T0 and T2, BBT scores improved from a mean of 3.0 (8.3) to 12.7 (17.3) blocks in RAT, but only from 3.8 (7.5) to 5.1 (9.8) blocks in the CT group.
  • UL motor activity improved more in the RAT than CT group (P= 0.02). Between T0 and T2, the S-WFMT score improved from a mean of 16% (21.4) to 39% (36.6) in RAT, but from 19% (23.6) to just 25% (33.1) in the CT group.
  • FMA-UE results showed a positive trend in favor of the RAT group (P = 0.058)
  • Social participation scores also improved significantly more in the RAT group (P = 0.01). Between T0 and T2, SISsb improved from a mean of 36% (21.4) to 59% (24.1) in the RAT group, but only from 45% (26.6) to 47% (31.5) in the CT group.

Discussion and conclusion

This study supports evidence that using RAT to partially substitute CT in the early rehabilitation phase is at least as effective, or even better, at improving UL and ADL function than CT alone. This study was also the first to assess the ICF social participation domain. The authors suggest greater improvements can be explained by the effect of the robotic device itself, which allows clinicians to deliver therapy using key motor recovery factors including high intensity and repetitive, task-oriented movement training.

Moreover, RAT’s long-term effectiveness is unrelated to post-rehabilitation lifestyle, with similar patient numbers from both groups returning either home or to a nursing home. The authors suggest their results should be confirmed in future multicentre studies involving larger participant numbers.

[i] Dehem S, et al. Effectiveness of upper-limb robotic-assisted therapy in the early rehabilitation phase after stroke: A single-blind, randomised, controlled trial. Ann Phys Rehabil Med (2019).

Blogpost – The arrival of REAtouch Lite® at Axinesis

petite fille jouant sur le REAtouch

Axinesis expands its intensive functional rehabilitation offer

We are delighted to announce the launch of our new REAtouch® Lite: the device for decentralized upper-limb rehabilitation in the rehabilitation centre or at home.

REAtouch® Lite is the portable version of the REAtouch®: our device for intensive bimanual functional upper-limb rehabilitation.

 

REAtouch® bimanual intensive therapy for upper limb rehabilitation

REAtouch® by Axinesis provides intensive bimanual functional rehabilitation based on the coordinated use of both hands.

Its 43” (95 x 53 cm) screen features a tangible user interface with up to 50 touchpoints, facilitating engaging touch and audio-visual interaction.

Designed to strengthen neuroplasticity and optimize functional outcomes, the device motivates patients to make more than 1,000 movements in one single session. This means 1,500 to 2,000 touchpoints, or browsing more than 60 meters on the screen.

 

petite fille jouant sur le REAtouch

With a portfolio of therapeutic games suited for patients of all ages, and a range of playful objects in multiple shapes for manipulation and construction tasks, the REAtouch® intensive bimanual therapy creates very high motor engagement through continued motivational stimulation.

 

The REAtouch® Lite device for decentralized rehabilitation

Afbeelding2

Covid-19 has prompted the development of a decentralized rehabilitation set-up. Axinesis has launched the REAtouch® Lite that can be used in a decentralized way in the rehabilitation centre or at home. REAtouch® Lite makes our intensive functional rehabilitation technology also accessible to patients who, for various reasons, are unable to take part in intensive therapy sessions in the rehabilitation centre.

It can be used as stand-alone or integrated in a network, connecting the REAtouch® and the REAtouch® Lite into one patient experience.

The REAtouch® Lite is available in a desktop version or integrated into an over-bed / over-chair table.

The 32-inch (73 x 41 cm) screen is protected by a tempered glass panel and is touch-sensitive, with up to 50 points of contact, allowing audiovisual interaction.

The REAtouch® Lite completes the Axinesis offer, covering the entire upper limb care pathway, from early rehabilitation in a care facility to a decentralized or homebased therapeutic support.

Blogpost – REAplan® now distributed in France by Dessintey

REAplan new device

AXINESIS entrusts DESSINTEY with the distribution of its REAplan® robot in France

With this collaboration, Dessintey proposes a unified offer IVS3 + REAplan® for a complete and intensive upper limb rehabilitation.

 

The upper limb, essential for daily life activities

Whether they are the result of a stroke, an orthopaedic trauma or chronic pain, partial or total upper limb deficiencies have a significant impact on the quality of life of patients: they cause difficulties in carrying out daily activities such as eating, washing, dressing, etc. 

 

Intention, planning, execution, motor control

Upper limb rehabilitation calls for an understanding of the individual components of the movement:

  • Action planning: Potential of actions – Intention & motor planification
  • Motor execution: Performance of movement and biofeedback 

Indeed, for many patients, motor performance is affected by an altered or non-existent movement command (body awareness, memory of motor functions, projection in time) and/or a difficulty in executing the movement (strength deficit, amplitude limits).

 

Complementary approaches to work on all stages of motor control

The combined IVS3 and REAplan® technologies constitute a complementary and innovative approach in the therapeutic arsenal for upper limb rehabilitation. They are based on four fundamental pillars:

  • Early and intensive treatment
  • Varied and complementary treatments and stimulations
  • Biofeedbacks to reinforce learning
  • Patient adherence and motivation

IVS3 (Intensive Visual Simulation), based on the principle of visual simulation of movement: a unique technology dedicated to motor planning and movement control.

REAplan® is an interactive end-effector robot for auto-adaptive intensive upper limb rehabilitation through therapeutic gamification: an innovative technology to facilitate and stimulate motor performance.

A commercial partnership for France

Feedback from therapists in the field has largely demonstrated the effectiveness and complementarity of this IVS3 + REAplan® combination. Both technologies aim to accelerate the patient’s return to autonomy, with innovative technologies promoting motor relearning and movement repetition.

Therefore, we are pleased to announce that the distribution of the REAplan® device will be handled by Dessintey in France. Together, we will be stronger to serve our clients across France, with a range of complementary products within a unified offer.

The Axinesis team will continue to market its REAtouch® and REAtouch® Lite devices directly.

 

About Dessintey

Since 2017, Dessintey has been developing and marketing intensive rehabilitation technologies to accelerate recovery and ensure greater patient autonomy. The company is also the French manufacturer of the IVS3 (Intensive Visual Simulation 3) device for upper limb rehabilitation in patients suffering from stroke, orthopaedic trauma or chronic pain.

 

About Axinesis

Axinesis is a medtech company, founded in 2015, specialised in neurorehabilitation. Axinesis’ mission is to enhance the functional recovery of all patients with motor and cognitive disorders throughout their care pathway, from centralized and supported care to decentralized and independent care. This mission is achieved through innovative, intensive rehabilitation technologies, such as the REAplan®, REAtouch® and REAtouch® Lite devices. These technologies are based on intensity and repetition of movements, combined with personalized therapeutic gamification, leading to improved motor and cognitive recovery, and improvements in activities of daily living and patient social participation.